<DOC>
	<DOCNO>NCT01899950</DOCNO>
	<brief_summary>Niemann-Pick Disease , Type C ( NPC ) rare neurodegenerative disorder wide clinical spectrum variable age onset . Classically , child NPC demonstrate neurological dysfunction cerebellar ataxia ( inability coordinate balance , gait , extremity eye movement ) , dysarthria ( difficulty speaking ) , seizures , vertical gaze palsy ( ability move eye direction ) motor impairment , dysphagia ( trouble swallow ) , psychotic episode , progressive dementia . There curative treatment NPC lethal disorder . The purpose protocol obtain baseline rate progression data clinical biochemical marker may later use outcome measure clinical trial . Specifically , study examine characterize longitudinal progression neurocognitive symptom NPC goal identify early marker disease progression may utilize late trial evaluate treatment efficacy .</brief_summary>
	<brief_title>Longitudinal Study Cognition With Niemann-Pick Disease , Type C</brief_title>
	<detailed_description />
	<mesh_term>Pick Disease Brain</mesh_term>
	<mesh_term>Aphasia , Primary Progressive</mesh_term>
	<mesh_term>Frontotemporal Dementia</mesh_term>
	<mesh_term>Niemann-Pick Diseases</mesh_term>
	<mesh_term>Niemann-Pick Disease , Type A</mesh_term>
	<mesh_term>Niemann-Pick Disease , Type C</mesh_term>
	<criteria>All individual age 2 year 99 establish diagnosis NiemannPick Disease , Type C ( biochemical molecular ) consider study . Patients NiemannPick Disease , Type C1 ( NPC1 ) NiemannPick Disease , Type C2 ( NPC2 ) mutation eligible participate . Participants least one follow eligible study : 1 . Individuals travel medical condition ill care home , 2 . Individuals stage 4 disease ( nonambulant vegetative disturbance ) 3 . Individuals exclude English primary language</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Niemann-Pick disease type C</keyword>
	<keyword>Lysosomal disease</keyword>
</DOC>